BioLife Solutions (NASDAQ:BLFS) Dips 5.5% This Week as Increasing Losses Might Not Be Inspiring Confidence Among Its Investors
BioLife Solutions (NASDAQ:BLFS) Dips 5.5% This Week as Increasing Losses Might Not Be Inspiring Confidence Among Its Investors
While not a mind-blowing move, it is good to see that the BioLife Solutions, Inc. (NASDAQ:BLFS) share price has gained 19% in the last three months. But that cannot eclipse the less-than-impressive returns over the last three years. After all, the share price is down 41% in the last three years, significantly under-performing the market.
虽然这并不是一个惊人的举动,但很高兴看到Biolife Solutions股票近三个月上涨了19%,但在过去三年中的走势表现并不令人印象深刻。毕竟,在过去三年中,股票价格下跌了41%,明显表现不佳,远远跑输了市场。
If the past week is anything to go by, investor sentiment for BioLife Solutions isn't positive, so let's see if there's a mismatch between fundamentals and the share price.
如果过去一周的股价表现是一个指引,BioLife Solutions的投资者情绪并不积极,因此让我们看看基本面和股价之间是否存在不匹配。
BioLife Solutions wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
在过去的十二个月中,Biolife Solutions没有盈利,因此其股价与每股收益(EPS)之间不太可能存在强相关性。可以说,营业收入是我们的下一个最佳选择。当公司没有盈利时,通常希望看到良好的营业收入增长。可以想象,当快速保持营收增长时,通常会导致快速利润增长。
In the last three years, BioLife Solutions saw its revenue grow by 21% per year, compound. That's well above most other pre-profit companies. The share price drop of 12% per year over three years would be considered disappointing by many, so you might argue the company is getting little credit for its impressive revenue growth. It's possible that the prior share price assumed unrealistically high future growth. Before considering a purchase, investors should consider how quickly expenses are growing, relative to revenue.
在过去的三年中,Biolife Solutions实现了每年21%的复合营业收入增长,超过了大多数其他尚未实现盈利的公司。三年内每年股价下跌12%,许多人都认为这令人失望,因此可以认为公司在其令人印象深刻的营业收入增长方面得到的认可有限。可能先前的股价假定了不切实际的未来增长。在考虑购买之前,投资者应考虑费用相对于营收的增长速度。
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
你可以在下面的图片中看到收入和营业收入随时间的变化情况(单击图表可查看精确值)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240605/0-2d840e0ad1e6ad8542ab7f7672a3b526-0-6d062e68931d7eaa57009e2a7fde9c3f.png/big)
Take a more thorough look at BioLife Solutions' financial health with this free report on its balance sheet.
下载此免费的财务报告以更全面地了解Biolife Solutions的财务状况。
A Different Perspective
不同的观点
Investors in BioLife Solutions had a tough year, with a total loss of 13%, against a market gain of about 24%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 4%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand BioLife Solutions better, we need to consider many other factors. To that end, you should be aware of the 2 warning signs we've spotted with BioLife Solutions .
BioLife Solutions的投资者过去一年面临着总亏损13%的困境,而市场涨幅约为24%。即使股票价格好的股票有时也会下跌,但在我们过于感兴趣之前,我们希望看到业务基本指标的改善。如果长期投资者可以接受每年五年4%的收益率,那么他们不会感到非常难过。最近的抛售可能是一个机会,因此可能值得检查基础数据,以寻找长期增长趋势的迹象。长期跟踪股价表现总是很有趣的。但要更好地了解Biolife Solutions,我们需要考虑许多其他因素。为此,您应该了解我们已发现的2个警告信号与Biolife Solutions有关。
Of course BioLife Solutions may not be the best stock to buy. So you may wish to see this free collection of growth stocks.
当然,Biolife Solutions可能不是最好的股票选择。因此,您可能希望查看这些增长型股票的免费收藏。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。